TW202404983A - Mci-1拮抗劑之鹽形式及溶劑化物 - Google Patents

Mci-1拮抗劑之鹽形式及溶劑化物 Download PDF

Info

Publication number
TW202404983A
TW202404983A TW112112762A TW112112762A TW202404983A TW 202404983 A TW202404983 A TW 202404983A TW 112112762 A TW112112762 A TW 112112762A TW 112112762 A TW112112762 A TW 112112762A TW 202404983 A TW202404983 A TW 202404983A
Authority
TW
Taiwan
Prior art keywords
crystalline form
amg
radiation
xrpd
crystalline
Prior art date
Application number
TW112112762A
Other languages
English (en)
Chinese (zh)
Inventor
亨利 莫禮森
傑森 S 泰德羅
史黛芬 D 派倫
科特妮 強森
崔維斯 賀斯敦
馬蘭尼 貝維爾
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202404983A publication Critical patent/TW202404983A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW112112762A 2022-04-05 2023-04-06 Mci-1拮抗劑之鹽形式及溶劑化物 TW202404983A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263327659P 2022-04-05 2022-04-05
US63/327,659 2022-04-05

Publications (1)

Publication Number Publication Date
TW202404983A true TW202404983A (zh) 2024-02-01

Family

ID=86386785

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112112762A TW202404983A (zh) 2022-04-05 2023-04-06 Mci-1拮抗劑之鹽形式及溶劑化物

Country Status (9)

Country Link
US (1) US12351588B2 (cg-RX-API-DMAC10.html)
EP (1) EP4504737A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025513774A (cg-RX-API-DMAC10.html)
AU (1) AU2023249146A1 (cg-RX-API-DMAC10.html)
CA (1) CA3254998A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024012192A (cg-RX-API-DMAC10.html)
TW (1) TW202404983A (cg-RX-API-DMAC10.html)
UY (1) UY40217A (cg-RX-API-DMAC10.html)
WO (1) WO2023196360A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119255998A (zh) 2022-05-04 2025-01-03 吉利德科学公司 特定mcl-1抑制剂的盐和多晶型物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1

Also Published As

Publication number Publication date
JP2025513774A (ja) 2025-04-30
CA3254998A1 (en) 2023-10-12
UY40217A (es) 2023-10-31
EP4504737A1 (en) 2025-02-12
WO2023196360A1 (en) 2023-10-12
MX2024012192A (es) 2024-11-08
US20230312602A1 (en) 2023-10-05
US12351588B2 (en) 2025-07-08
AU2023249146A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP6211072B2 (ja) ダサチニブと、選択された共結晶形成剤とを含んでなる多成分結晶
ES2750676T5 (en) Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation
EP3946364B1 (en) Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof
JP6370377B2 (ja) 非晶質形態のダサチニブの塩
JP7825636B2 (ja) (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
JP2025131661A (ja) 2-(5-(4-(2-モルホリノエトキシ)フェニル)ピリジン-2-イル)-n-ベンジルアセトアミドの固体形態
KR20160023879A (ko) 결정질 형태의 다사티닙 염
US12351588B2 (en) Salt forms and solvates of Mcl-1 antagonists
JP2016512518A (ja) ベムラフェニブ塩酸塩の固体形態
TW202404982A (zh) Mci-1拮抗劑之無定形及結晶形式
US20250115622A1 (en) Crystalline Forms Of An MCL-1 Inhibitor
CN115385871A (zh) 舒欣啶盐
US20250122224A1 (en) Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397)
JP5959617B2 (ja) オタミキサバンの安息香酸塩
WO2006073290A1 (en) A dicarboxylic acid salt of sibutramine
TW202440586A (zh) 口奈啶化合物的固體形式
CN110156704B (zh) 1,2,4-三唑硫醚衍生物及其晶体结构与应用
TW202216726A (zh) 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
CN110678464A (zh) 马赛替尼的晶型
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
KR20210017070A (ko) 신규한 티카그렐러의 결정형, 이의 제조방법 또는 용도
IL297877A (en) Polymorphic forms of (r)-oxybutynin hydrochloride